Alife Health (Alife), a leading provider of AI-powered tools to advance the in-vitro fertilization (IVF) process, is excited to expand its partnership with US Fertility, the nation’s largest partnership of physician-owned fertility practices. In a move set to reshape the industry, US Fertility and Alife will provide each patient with her personalized, AI-driven IVF laboratory summary report, including embryo images, laboratory-generated grading, clinical significance, and next steps. This is a landmark in the integration of AI technology into reproductive healthcare. Further, it solidifies US Fertility’s leadership in innovation and Alife’s position as the go-to provider of AI-powered solutions for IVF.

With more than 100 clinics and 32 IVF laboratories across the United States, US Fertility serves tens of thousands of patients annually on their journeys to build families. The nationwide adoption of Alife technology represents US Fertility’s continued commitment to enhancing the precision, efficiency, and consistency of their IVF processes, with the goal of providing optimal and individualized care to every patient.

“Partnering with Alife is a transformative step forward for US Fertility,” says Richard Jennings, Chief Executive Officer of US Fertility. “Alife’s embryo imaging technology furnishes reports sent directly to patients. This facilitates patient engagement with the IVF lab. By embracing AI, US Fertility is setting a new industry standard in how IVF is delivered, streamlining clinical workflow and optimizing patient experience across our nationwide network.”

Alife’s Embryo Assist™ tool is designed to streamline and digitize the traditionally manual process of embryo grading. With seamless microscope integration and real-time connection to electronic medical records (EMR), the software allows embryologists to capture, rank, and organize embryo data in one place, reducing the time spent on manual documentation. The tool not only saves valuable time—up to 15 minutes per cycle per embryologist—but also provides real-time lab updates, ensuring embryologists have immediate access to the latest data for faster and more informed decision-making. Additionally, the software generates personalized embryo reports for patients, helping them better understand their IVF journey with clear, data-driven insights. This combination of operational efficiency and patient-centric reporting elevates the overall IVF experience.

Kate Devine, MD, Medical Director and Chief Research Officer of US Fertility, added: “Integrating AI via Alife’s state-of-the-art, direct-to-patient embryo vitrification reporting marks an exciting evolution for US Fertility. We’ve seen first-hand how it boosts operational efficiencies and elevates patient experience.”

“This partnership with US Fertility is a true gamechanger for the fertility industry,” says Melissa Teran, Chief Executive Officer of Alife. “As the largest player in the field, their adoption of our tool is a huge vote of confidence in Alife’s technological approach to IVF. We are honored to help optimize their embryology reporting and provide their teams with the tools they need to improve patient care. This collaboration demonstrates how AI is poised to play a pivotal role in the future of fertility treatments.”

The nationwide rollout of Alife technology by US Fertility marks a new era of efficiency, precision, and data-driven decision-making for fertility labs, ultimately advancing the way IVF is performed on a large scale.